140,000 Shares in Stevanato Group S.p.A. (NYSE:STVN) Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new stake in Stevanato Group S.p.A. (NYSE:STVN) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 140,000 shares of the company’s stock, valued at approximately $2,800,000.

Several other large investors also recently modified their holdings of the company. Hilltop National Bank raised its position in shares of Stevanato Group by 34.3% during the second quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock worth $81,000 after purchasing an additional 1,122 shares during the period. nVerses Capital LLC purchased a new position in Stevanato Group in the third quarter valued at approximately $84,000. Harbor Capital Advisors Inc. grew its stake in shares of Stevanato Group by 109.1% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 8,867 shares of the company’s stock worth $163,000 after acquiring an additional 4,626 shares during the period. Raymond James Trust N.A. increased its holdings in Stevanato Group by 18.7% in the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock worth $188,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Stevanato Group by 59.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock valued at $219,000 after purchasing an additional 4,441 shares during the last quarter.

Stevanato Group Price Performance

STVN traded down €0.19 ($0.20) on Thursday, hitting €20.56 ($21.87). 855,300 shares of the company were exchanged, compared to its average volume of 513,805. Stevanato Group S.p.A. has a 12 month low of €16.56 ($17.62) and a 12 month high of €34.73 ($36.95). The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The firm has a fifty day simple moving average of €19.62 and a two-hundred day simple moving average of €20.11.

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). The company had revenue of €277.90 million during the quarter, compared to the consensus estimate of €274.36 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.16 earnings per share. Equities research analysts forecast that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Citigroup lowered their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.